King Pharmaceuticals: court upholds patent claims for Altace, rules agains Lupin

By Lisa Kerner

Charlotte, N.C., July 18 - King Pharmaceuticals, Inc. said the U.S. District Court for the Eastern District of Virginia, Norfolk Division, upheld the validity of U.S. Patent No. 5,061,722 (the 722 patent), the composition of matter patent covering Altace (ramipril).

The court previously granted summary judgment in favor of King finding that Lupin Ltd.'s proposed generic product infringed King's 722 patent.

In addition, the court dismissed Lupin's unenforceability claims.

King is a vertically integrated branded pharmaceutical company based in Bristol, Tenn.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.